Examining the link between pancreatic steatosis and pancreatic cysts and cancer
The Emerging Issue - Pancreatic Steatosis Prevalence in Pancreatic Cystic Neoplasms and Adenocarcinoma: Insights From a Single-center Retrospective Study
This study is trying to see if having fat in the pancreas is more common in people with pancreatic cysts that could turn into cancer and those with pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 66 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Carol Davila University of Medicine and Pharmacy Academic / other |
| Locations | 1 site (Bucharest, Sector 1) |
| Trial ID | NCT06867172 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prevalence of pancreatic steatosis in patients with pancreatic cystic neoplasms and pancreatic adenocarcinoma. It will utilize imaging techniques such as computerized tomography (CT) and endosonography (EUS) to evaluate the presence of steatosis in these conditions. The primary goal is to determine if pancreatic steatosis is more common in cystic lesions that have a risk of cancer development. Additionally, the study will explore the prevalence of steatosis in patients diagnosed with pancreatic adenocarcinoma.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 or older with at least one pancreatic cystic lesion or those diagnosed with pancreatic adenocarcinoma.
Not a fit: Patients with significant alcohol consumption or those with contraindications for endoscopy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the relationship between pancreatic steatosis and cancer risk, potentially leading to improved diagnostic and treatment strategies.
How similar studies have performed: While the relationship between pancreatic steatosis and pancreatic cancer is emerging, this specific investigation into cystic neoplasms is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam). Exclusion Criteria: * No evidence of written informed consent * Patients with contraindications for endoscopy due to comorbidities * Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary) * Acute pancreatitis at baseline imaging * Pancreatic surgery at baseline imaging in our department * Splenectomy * Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Where this trial is running
Bucharest, Sector 1
- Prof Dr Agrippa Ionescu; Clinical Emergency Hospital — Bucharest, Sector 1, Romania (Recruiting)
Study contacts
- Study coordinator: Catalina Vladut, MD PhD
- Email: drcatalinavladut@gmail.com
- Phone: +40751015445
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.